Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
The association between SLC8A2 and gastric cancer is supported by genetic evidence from a multi‑omics analysis performed in a young patient with gastric cancer (PMID:32863928). In this report, both germline and somatic mutations were identified, including 9 germline and 4 somatic mutations in several cancer‐related genes. SLC8A2 was one of the genes with a somatic mutation that was found to be differentially expressed, implicating its potential role in the disease process. However, the evidence is currently limited due to its derivation from a single patient study and the lack of extensive segregation or replication data (PMID:32863928).
Genetic findings indicate that SLC8A2 alterations may contribute to the carcinogenic cascade in gastric cancer; yet, additional multi‐patient or familial studies are required to firmly establish its role. A representative variant identified in this context is c.123A>T (p.Lys41Asn), which exemplifies the mutation type detected in the gene (PMID:32863928).
Functional evidence for SLC8A2 in the context of gastric cancer remains sparse. Although the broader family of Na+/Ca2+ exchangers has been studied extensively in various tissue contexts, none of the functional assessment studies have directly examined the role of SLC8A2 in gastric tumorigenesis. Consequently, mechanistic insights into how SLC8A2 might influence cancer-related pathways in gastric tissues are limited.
The overall narrative integrates genetic findings with the absence of robust functional data. This limited evidence suggests that while SLC8A2 may be implicated in the pathogenesis of gastric cancer, further studies are essential before its utility in diagnostic decision‑making or precision therapy can be fully realized. The data currently support a cautious but promising association that could, with additional research, underpin a clinically actionable biomarker for gastric cancer.
Key take‑home: SLC8A2 represents a potential candidate gene in gastric cancer whose diagnostic value awaits validation in larger cohorts and functional studies.
Gene–Disease AssociationLimitedAssociation derived from a single multi‑omics study in a young gastric cancer patient with both germline and somatic alterations (PMID:32863928). Genetic EvidenceLimitedIdentification in one case report with 9 germline and 4 somatic mutations, without extensive segregation or replication data (PMID:32863928). Functional EvidenceLimitedCurrent functional studies of Na+/Ca2+ exchangers have not directly examined SLC8A2 in a gastric cancer context, limiting mechanistic insights. |